Differentiation of low molecular weight heparins in treatment of acute deep vein thrombosis

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue SUPPL. 3, 1999, Pages 107-112

  Davidson, Bruce L ^a  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

Deep vein thrombosis; Efficacy; Low molecular weight heparin; Treatment

Indexed keywords

DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; TINZAPARIN;

ANTICOAGULANT THERAPY; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; HUMAN; PRIORITY JOURNAL;

AGED; ANIMALS; CLINICAL TRIALS; DRUG EVALUATION; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MIDDLE AGED; VENOUS THROMBOSIS;

EID: 0032745736     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Hirsh J. Comparison of ihe relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of deep venous thrombosis. Semin Hematol 1999:34:20-25
2. Lensing AWA, Prins M, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low molecular weight heparins. Arch Intern Med 1995:155:601 (abstract)
3. Leizorovicz A. Comparison of the efficacy and safety of LMWHs and unfractionated heparin in the initial treatment of deep venous thrombsis. Drugs 1996;52 (suppl 7):30-37
4. Planes A, Vochelle N, Fagola M, Bellaud M. Comparison of two low molecular weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Reviparin Study Group. Blood Coag Fibrinolysis 1998;9: 499-505
5. Planes A, Samama MM, Lensing AW et al. Prevention of deep vein thrombosis after hip replacement-comparison between two low molecular heparins, tinzaparin, and enoxaparin. Thromb Haemost 1999:81:22-25
6. Partsch H, Kechavarz B, Mostbeck A, Köhn H, Lipp C. Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low molecular weight heparin. J Vase Surg 1996; 24:774-782
7. Wells P, Kovacs M, Bormanis J, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low molecular weight heparin. Arch Intern Med 1998:158:1809 (abstract)
8. Enoxaparin Clinical Trial Group. A multicenter clinical trial comparing once- and twice-daily subcutaneous enoxaparin and intravenous heparin in the treatment of acute deep vein thrombosis. Presented at ASH Congress, 1997, Abstract 1305
9. Levine M, Gent M, Hirsh J, et al. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996:334:677-681
10. Charbonnier BA, Fiessinger J-N, Banga JD, et ai. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep-vein thrombosis. FRAXODI Group. Thromb Haemost 1998;79:897-901
11. Prandoni P, Lensing AWA, Buller HR, et al. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-445
12. Koopman M, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home. N Engl J Med 1996;334:682-687
13. Columbus Investigators. Low molecular weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997:337:657-662
14. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992:326:975-982
15. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low molecular weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997:337:663-669
16. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of, and prophylaxis for, venous thromboembolism in hospital patients. Br Med J 1992:305:567-574
17. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983;62:14-31
18. Levine M, Gent M, Hirsh J, et al. The thrombogenic effect of an- ticancer drug therapy in women with stage II breast cancer. N EnglJMed 1988;318:404-407
19. Leizorovicz A, Simonneau G, Décousus H, Boissel JP. Comparison of efficacy and safety of LMWHs and unfractionated heparin in initial treatment of deep venous thrombosis. Br Med J 1994:309:299-304
20. Collignon F, Frydman A, Caplain H, et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins-dalteparin, enoxaparin, and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995:73:630-640
21. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315: 1109-1114
22. Mismetti P, Reynaud J, Tardy-Poneet-B, et al. Chrono-pharmacological study of once-daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of dalteparin) in ten healthy volunteers. Thromb Haemost 1995;74:660-666
23. Eriksson BI, Soderberg K, Widlund L, et al. A comparative study of three low molecular weight heparins (LMWH) and unfractionated heparin in healthy volunteers. Thromb Haemost 1995;73:398-101